Reversal of intense neuromuscular blockade following infusion of atracurium. 1990

J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
Department of Anesthesia, Herlev Hospital, Copenhagen, Denmark.

In order to evaluate reversal time from very intense neuromuscular blockade caused by a continuous infusion of atracurium, the time course of neostigmine induced reversal from different levels of neuromuscular blockade was evaluated using the post-tetanic count (PTC) and the train-of-four (TOF) in 30 patients anesthetized with nitrous oxide, fentanyl, and thiopental. Reversal time (time from administration of neostigmine at different PTC levels to a TOF ratio of 0.7) was found to depend upon the degree of blockade at the time of reversal. Median reversal time from a PTC of 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, and greater than 13 (but less than 10% twitch height) to a TOF ratio of 0.7 was 31, 23, 19, 18, 14, and 13 min, respectively. Spontaneous recovery from PTC level of 1-2, when atracurium infusion was stopped, to a PTC level at which antagonism was induced and reversal time were both correlated to the square root of the PTC. Total recovery time (spontaneous recovery plus reversal time) was not shortened by an early injection of neostigmine. It is concluded that neostigmine administration during intense neuromuscular blockade following atracurium infusion does not shorten total recovery time and offers no clinical advantages.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009388 Neostigmine A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier. Synstigmin,Neostigmine Bromide,Neostigmine Methylsulfate,Polstigmine,Proserine,Prostigmin,Prostigmine,Prozerin,Syntostigmine,Bromide, Neostigmine,Methylsulfate, Neostigmine
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D009469 Neuromuscular Junction The synapse between a neuron and a muscle. Myoneural Junction,Nerve-Muscle Preparation,Junction, Myoneural,Junction, Neuromuscular,Junctions, Myoneural,Junctions, Neuromuscular,Myoneural Junctions,Nerve Muscle Preparation,Nerve-Muscle Preparations,Neuromuscular Junctions,Preparation, Nerve-Muscle,Preparations, Nerve-Muscle
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000769 Anesthesia, Inhalation Anesthesia caused by the breathing of anesthetic gases or vapors or by insufflating anesthetic gases or vapors into the respiratory tract. Insufflation Anesthesia,Anesthesia, Insufflation,Inhalation Anesthesia
D001279 Atracurium A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. Atracurium Besylate,Atracurium Dibesylate,33 A 74,Atracurium Besilate,BW-33A,Relatrac,Tracrium,A 74, 33,BW 33A,BW33A,Besilate, Atracurium

Related Publications

J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
November 1989, Anesthesia and analgesia,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
September 1996, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
August 1997, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
May 1986, British journal of anaesthesia,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
March 1986, Canadian Anaesthetists' Society journal,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
September 1986, Canadian Anaesthetists' Society journal,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
November 1987, Anaesthesia,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
January 1986, British journal of anaesthesia,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
January 1990, Journal of clinical anesthesia,
J Engbaek, and D Ostergaard, and L T Skovgaard, and J Viby-Mogensen
June 1993, Anaesthesia and intensive care,
Copied contents to your clipboard!